Doesnt seem to be an explanation and the stock is down. Looks like a shift from interim data in June to top line data in July. Not sure what the significance is there. I saw a couple of reports recently suggesting the FDA was managing it's workload (I.e. cancelling meetings) by shifting the criteria on which those meeting happened. Often by demanding greater data packages before proceeding
...more